Sort
4,870 grants matching “glp 1”
Development of novel NLRP3 inflammasome inhibitors for intervening in Alzheimer's disease
$1,426,573Shijun Zhang · Virginia Commonwealth University · U01 · FY2022 · AG
Development of a novel dual HIF-α inhibitor and inducer of ferroptosis for kidney cancer
$1,425,000Robert Lippert · Kuda Therapeutics, Inc. · R44 · FY2022 · CA
Development of a novel, regenerative therapy to reverse synapse loss in Alzheimer's Disease
$1,419,610Peter W Vanderklish · Spinogenix, Inc. · R44 · FY2023 · AG
âGLP-1 Outcomes with people Using Psychoactive Substances (GLOW-UPS): a multi-stage, multi-site trial among persons involved in the criminal-legal system
$1,418,065Joshua D Lee · New York University School Of Medicine · UM1 · FY2025 · DA
Novel compounds for the treatment of systemic sclerosis-associated interstitial lung disease
$1,417,658Scott Scarneo · Eydis Bio, Inc. · R44 · FY2025 · HL
Preclinical Development of a Selective Suppressor of Neuroinflammation for MCI/AD
$1,416,252Linda J Van Eldik · University Of Kentucky · U01 · FY2015 · AG
Preclinical development of a vaccine for Nipah virus
$1,415,990Thomas William Geisbert · University Of Texas Med Br Galveston · R01 · FY2021 · AI
RNAi Therapy for Spinocerebellar Ataxia Type 1
$1,414,317Beverly L Davidson · Children'S Hosp Of Philadelphia · UH3 · FY2022 · NS
Gene Therapy for Brain Tumors
$1,412,570Fred H Hochberg · Massachusetts General Hospital · P01 · FY2009 · CA
Peripherally-Restricted Long-Acting Somatostatin Receptor 4 (LA-SSTR4) Agonists for Pain
$1,410,027Pierre Riviere · Peptide Logic, Llc · R44 · FY2020 · NS
Preclinical Development of a Selective Suppressor of Neuroinflammation for MCI/AD
$1,403,404Linda J Van Eldik · University Of Kentucky · U01 · FY2016 · AG
Development of novel NLRP3 inflammasome inhibitors for intervening in Alzheimer's disease
$1,403,321Shijun Zhang · Virginia Commonwealth University · U01 · FY2024 · AG
Development of novel NLRP3 inflammasome inhibitors for intervening in Alzheimer's disease
$1,403,321Shijun Zhang · Virginia Commonwealth University · U01 · FY2023 · AG
Development of an M1 PAM experimental therapeutic for schizophrenia
$1,401,867P Jeffrey Conn · Vanderbilt University · U19 · FY2017 · MH
fMRI Study of Motivation, Decision-Making, Reward, Risk, Aversion, Craving, impulsivity, and Stress in Alcohol Use Disorders
$1,401,474Abdolreza Momenan · National Institute On Alcohol Abuse And Alcoholism · ZIA · FY2015 · AA
Gene Therapy for Brain Tumors
$1,400,000Fred H Hochberg · Massachusetts General Hospital · P01 · FY2006 · CA
EVVS: Endoscopic Venous Valve System
$1,399,713Janet Galtes · Venarum Medical, Llc · R44 · FY2019 · HL
DATA AND STATISTICAL ANALYSIS FOR GLP-1 AS AN ADJUNCT TO BUPRENORPHINE. MAY 21, 2025 - FEBRUARY 29, 2028. N01DA-22-2253. TASK ORDER NO. 75N95025F00002 (TO26).
$1,397,875Jennifer McCormack · The Emmes Company, Llc · N01 · FY2025 · DA
Research Project I: AAV-CRISPR to Treat Huntington's Disease
$1,396,185Russell Lonser · University Of California Berkeley · U19 · FY2024 · NS
Development of TP-317 for the Induction and Maintenance of Remission in Ulcerative Colitis Patients
$1,396,059Frank Sciavolino · Thetis Pharmaceuticals, Llc · R44 · FY2018 · DK
Arterial-Mimetic Grafts Molded from Purified Proteins
$1,395,176David B Masters · Gel-Del Technologies, Inc. · R44 · FY2011 · HL
Development of a novel adjuvant for vaccine sparing
$1,393,822Sara Lustigman · New York Blood Center · R01 · FY2013 · AI
BioSphincter to Treat Fecal Incontinence. Phase 1/2 Clinical Trial. SBIR Phase IIB
$1,393,626Khalil N Bitar · Cellf-Bio Inc · R44 · FY2021 · DK
BioSphincter to Treat Fecal Incontinence. Phase 1/2 Clinical Trial. SBIR Phase IIB
$1,393,626Khalil N Bitar · Cellf-Bio Inc · R44 · FY2019 · DK
Supplemental Request: Therapeutic APOE2 overexpression for early Alzheimer's disease
$1,393,438Beverly L Davidson · Children'S Hosp Of Philadelphia · U01 · FY2022 · NS